Skip to content

The impact of sex differences on cardiovascular disease in axial spondyloarthritis. From micro- to macrocirculation.

The impact of sex differences on cardiovascular disease in axial spondyloarthritis. From micro- to macrocirculation. - Burning heart

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON57330
Enrollment
Unknown
Registered
2025-03-03
Start date
2024-09-01
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

axial spondyloarthritis Bechterew disease

Interventions

None listed

Sponsors

Radboud Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, patients must meet all of the following criteria: • 18 years or older • radiographic axial spondyloarthritis according to ASAS criteria: Assessment of Spondyloarthritis International Society (ASAS) • HLA-B27 positive • Able to read, write and sufficiently communicate in Dutch • Written informed consent

Exclusion criteria

Exclusion criteria: • Contraindications to CMR or CCTA (e.g. claustrophobia, ferromagnetic implants, known allergy to iodinated or gadolinium-based contrast agents, weight or size exceeding the limits of the CMR or CCTA scanner. • Contraindications to intravenous adenosine administration (e.g. Chronic Obstructive Pulmonary Disease stage IV or asthma, systemic hypotension with mean arterial blood pressure

Design outcomes

Primary

MeasureTime frame
The primary endpoints of this study are: - CAC-score -->Calciumscore (low, medium,high)

Secondary

MeasureTime frame
->Endpoints derived from CMR (morphologic and functional parameters) ->Endpoints derived from CT coronary angiography (morphologic and functional parameters) -> Features on electrocardiogram -> The cardiovascular risk profile: a. Lipid profile: HDL cholesterol, LDL cholesterol, total cholesterol, triglycerides, apolipoprotein A-1 and apolipoprotein B b. Biomarkers of inflammation, including C-reactive protein and erythrocyte sedimentation rate c. Hemodynamic parameters: blood pressure, pulse rate. d. SCORE2 risk prediction

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)